{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:02:03Z","timestamp":1770267723559,"version":"3.49.0"},"reference-count":46,"publisher":"Academy of Managed Care Pharmacy","issue":"2-a Suppl","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.18553\/jmcp.2026.32.2-a.s1","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:00:56Z","timestamp":1770220856000},"page":"S1-S12","source":"Crossref","is-referenced-by-count":0,"title":["AMCP Market Insights: The role of managed care in improving patient care in mucopolysaccharidoses"],"prefix":"10.18553","volume":"32","author":[{"given":"Bridget","family":"Flavin","sequence":"first","affiliation":[{"name":"Connected Content, Ltd., Boulder, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Haumschild","sequence":"additional","affiliation":[{"name":"Emory Healthcare and Winship Cancer Institute, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri K.","family":"Klein","sequence":"additional","affiliation":[{"name":"National MPS Society, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"McKay","sequence":"additional","affiliation":[{"name":"Project Alive, Crestline, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Mok","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Oakland, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"Cure Sanfilippo Foundation, Lexington County, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Rice","sequence":"additional","affiliation":[{"name":"Michelle Rice & Associates, LLC, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Stephens","sequence":"additional","affiliation":[{"name":"Muenzer MPS Research & Treatment Center, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Stoltz","sequence":"additional","affiliation":[{"name":"Michelle Rice & Associates, LLC, Chandler, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7818","reference":[{"key":"r1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker394"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.1177\/2326409818800346"},{"key":"r3","unstructured":"Centers for Disease Control and Prevention. About Newborn Screening. Published December 17, 2024. Accessed October 11, 2025. https:\/\/www.cdc.gov\/newborn-screening\/about\/index.html"},{"key":"r4","unstructured":"Health Resources & Services Administration. US Advisory Committee on Heritable Disorders in Newborns and Children: Recommended Uniform Screening Panel. Last reviewed July 2024. Accessed October 11, 2025. https:\/\/www.hrsa.gov\/advisory-committees\/heritable-disorders\/rusp"},{"key":"r5","unstructured":"NewSTEPs. Newborn Screening Status for All Disorders. Accessed October 11, 2025. https:\/\/www.newsteps.org\/resources\/data-visualizations\/newborn-screening-status-all-disorders"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.3390\/ijns6040091"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.10.012"},{"key":"r8","unstructured":"Muenzer J. Overview of mucopolysaccharidoses (MPS). AMCP Market Insights: The Role of Managed Care in Improving Patient Care in Mucopolysaccharidoses; September 2025; virtual."},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.02.012"},{"key":"r10","unstructured":"Muenzer J. Advances in Treatment for MPS. AMCP Market Insights: The Role of Managed Care in Improving Patient Care in Mucopolysaccharidoses; September 2025; virtual."},{"key":"r11","unstructured":"National Library of Medicine. ClinicalTrials.gov Search. Accessed October 22, 2025. https:\/\/clinicaltrials.gov"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041258"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-022-00100-2"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104346"},{"key":"r15","unstructured":"U.S. Food and Drug Administration. Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review. June 12, 2023. Accessed October 25, 2025. https:\/\/www.fda.gov\/patients\/learn-about-drug-and-device-approvals\/fast-track-breakthrough-therapy-accelerated-approval-priority-review"},{"key":"r16","unstructured":"MPS Society. Barriers and facilitators to clinical trial participation: Improving accessibility, logistics and awareness. Presented February 2025. Accessed October 25, 2025. https:\/\/mpssociety.org.uk\/files\/fabry-matters-conference-poster_final.pdf"},{"key":"r17","unstructured":"UNC School of Medicine. Muenzer MPS Center. Accessed October 20, 2025. https:\/\/www.med.unc.edu\/pediatrics\/muenzer-mps-center\/"},{"key":"r18","unstructured":"Telehealth.HHS.gov. Telehealth policy updates. Updated March 20, 2025. Accessed October 26, 2025. https:\/\/telehealth.hhs.gov\/providers\/telehealth-policy\/telehealth-policy-updates"},{"key":"r19","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02484-6"},{"key":"r20","unstructured":"ICER. Managing the Challenges of Paying for Gene Therapy: Strategies for Market Action and Policy Reform. Published April 23, 2024. Accessed December 10, 2025. https:\/\/icer.org\/wp-content\/uploads\/2024\/04\/Managing-the-Challenges-of-Paying-for-Gene-Therapy-_-ICER-NEWDIGS-White-Paper-2024_final.pdf"},{"key":"r21","unstructured":"AMCP. In the World of Value-Based Care, Words Matter: A Lexicon for Value-Based Purchasing. Published December 2023. Accessed December 10, 2025. https:\/\/www.amcp.org\/sites\/default\/files\/2023-12\/VBCLexicon-OnePager-DEC-2023.pdf"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11020273"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2021-108061"},{"key":"r24","volume-title":"Package insert","author":"Aldurazyme","year":"2023"},{"key":"r25","unstructured":"Elaprase. Package insert. Takeda Pharmaceuticals U.S.A., Inc.; 2025."},{"key":"r26","volume-title":"Package insert","author":"Vimizim","year":"2019"},{"key":"r27","volume-title":"Package insert","author":"Naglazyme","year":"2024"},{"key":"r28","volume-title":"Package insert","author":"Mepsevii","year":"2020"},{"key":"r29","unstructured":"National Library of Medicine. ClinicalTrials.gov. Updated continuously. Accessed September 24, 2025. https:\/\/clinicaltrials.gov"},{"key":"r30","unstructured":"Denali. Our Pipeline. Accessed October 18, 2025. https:\/\/www.denalitherapeutics.com\/pipeline"},{"key":"r31","unstructured":"Meglio M. FDA Delays Review Deadline for Hunter Syndrome Agent Tividenofusp Alfa. Neurology Live. Published October 14, 2025. Accessed November 5, 2025. https:\/\/www.neurologylive.com\/view\/fda-delays-review-deadline-hunter-syndrome-agent-tividenofusp-alfa"},{"key":"r32","unstructured":"GC Biopharma USA. Innovation. Accessed October 18, 2025. https:\/\/gcbiopharma.us\/product_pipeline.html"},{"key":"r33","unstructured":"JCR Pharmaceuticals. R&D\/Production. Published May 20, 2025. Accessed October 18, 2025. https:\/\/www.jcrpharm.co.jp\/en\/site\/en\/biopharmaceutical\/pdf\/pipeline_en.pdf"},{"key":"r34","unstructured":"Spruce Biosciences. Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB). Published October 6, 2025. Accessed October 20, 2025. https:\/\/investors.sprucebio.com\/news-releases\/news-release-details\/spruce-biosciences-receives-us-fda-breakthrough-therapy"},{"key":"r35","unstructured":"Generium Pharmaceuticals. Pipeline. Accessed October 18, 2025. https:\/\/www.generium.ru\/en\/pipeline\/"},{"key":"r36","unstructured":"UCSF Benioff Children\u2019s Fetal Treatment Center. PEARL Trial. Accessed September 24, 2025. https:\/\/fetus.ucsf.edu\/pearl-trial\/"},{"key":"r37","unstructured":"Regenxbio. Therapeutic Pipeline. Accessed September 24, 2025. https:\/\/www.regenxbio.com\/therapeutic-programs\/"},{"key":"r38","unstructured":"PR Newswire. REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I\/II\/III CAMPSIITE\n                      \u00ae\n                      Trial of RGX-121 for Treatment of MPS II. Published September 5, 2025. Accessed October 20, 2025. https:\/\/www.prnewswire.com\/news-releases\/regenxbio-presents-positive-twelve-month-pivotal-data-from-phase-iiiiii-campsiite-trial-of-rgx-121-for-treatment-of-mps-ii-302547381.html#:\u223c:text\u2009=\u2009In%20August%202025%2C%20the%20FDA,application%20by%20February%208%2C%202026"},{"key":"r39","unstructured":"Ultragenyx. Our pipeline. Accessed September 24, 2025. https:\/\/www.ultragenyx.com\/our-research\/pipeline\/"},{"key":"r40","unstructured":"Ultragenyx. Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA). Published July 11, 2025. Accessed September 24, 2025. https:\/\/ir.ultragenyx.com\/news-releases\/news-release-details\/ultragenyx-receives-complete-response-letter-fda-ux111-aav-gene"},{"key":"r41","unstructured":"Orchard Therapeutics. Our Portfolio and Focus. Accessed November 5, 2025. https:\/\/www.orchard-tx.com\/approach\/pipeline\/"},{"key":"r42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03079-3"},{"key":"r43","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12715"},{"key":"r44","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics9040226"},{"key":"r45","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-016-9974-5"},{"key":"r46","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12467"}],"container-title":["Journal of Managed Care &amp; Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:01:03Z","timestamp":1770220863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.32.2-a.s1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":46,"journal-issue":{"issue":"2-a Suppl","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.18553\/jmcp.2026.32.2-a.s1"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.32.2-a.s1","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}